Drug resistance beyond extensively drugresistant tuberculosis: Individual patient data meta-analysis

Giovanni Battista Migliori, Giovanni Sotgiu, Neel R. Gandhi, Dennis Falzon, Kathryn DeRiemer, Rosella Centis, Maria Graciela Hollm-Delgado, Domingo Palmero, Carlos Pérez-Guzmán, Mario H. Vargas, Lia D'Ambrosio, Antonio Spanevello, Melissa Bauer, Edward D. Chan, H. Simon Schaaf, Salmaan Keshavjee, Timothy H. Holtz, Dick Menzies, S. Ahuja, D. AshkinM. Avendano, R. Banerjee, J. N. Bayona, M. C. Becerra, A. Benedetti, M. Burgos, C. Y. Chiang, H. Cox, N. H. Dung, D. Enarson, K. Flanagan, J. Flood, L. Garcia-Garcia, R. M. Granich, M. D. Iseman, L. G. Jarlsberg, H. R. Kim, W. J. Koh, J. Lancaster, C. Lange, W. C M De Lange, V. Leimane, C. C. Leung, J. Li, S. P. Mishustin, C. D. Mitnick, M. Narita, P. O'Riordan, M. Pai, S. K. Park, G. Pasvol, J. Pena, A. Ponce-De-Leon, M. I D Quelapio, V. Riekstina, J. Robert, S. Royce, K. J. Seung, L. Shah, T. S. Shim, S. S. Shin, Y. Shiraishi, J. Sifuentes-Osornio, M. J. Strand, P. Tabarsi, T. E. Tupasi, R. Van Altena, M. Van Der Walt, T. S. Van Der Werf, P. Viiklepp, J. Westenhouse, W. W. Yew, J. J. Yim

研究成果: 雜誌貢獻文章同行評審

200 引文 斯高帕斯(Scopus)


The broadest pattern of tuberculosis (TB) drug resistance for which a consensus definition exists is extensively drug-resistant (XDR)-TB. It is not known if additional drug resistance portends worsened patient outcomes. This study compares treatment outcomes of XDR-TB patients with and without additional resistance in order to explore the need for a new definition. Individual patient data on XDR-TB outcomes were included in a meta-analysis comparing outcomes between XDR alone and three nonmutually exclusive XDR-TB patient groups: XDR plus resistance to all the second-line injectables (sli) and capreomycin and kanamycin/amikacin (XDR+2sli) XDR plus resistance to second-line injectables and to more than one group 4 drug, i.e. ethionamide/protionamide, cycloserine/ terizidone or para-aminosalicylic acid (XDR+sliG4) and XDR+sliG4 plus resistance to ethambutol and/or pyrazinamide (XDR+sliG4EZ). Of 405 XDR-TB cases, 301 were XDR alone, 68 XDR+2sli, 48 XDR+sliG4 and 42 XDR+sliG4EZ. In multivariate analysis, the odds of cure were significantly lower in XDR+2sli (adjusted OR 0.4, 95%CI 0.2- 0.8) compared to XDR alone, while odds of failure and death were higher in all XDR patients with additional resistance (adjusted OR 2.6-2.8). Patients with additional resistance beyond XDR-TB showed poorer outcomes. Limitations in availability, accuracy and reproducibility of current drug susceptibility testing methods preclude the adoption of a useful definition beyond the one currently used for XDR-TB.

頁(從 - 到)169-179
期刊European Respiratory Journal
出版狀態已發佈 - 七月 1 2013

ASJC Scopus subject areas

  • 肺和呼吸系統醫學


深入研究「Drug resistance beyond extensively drugresistant tuberculosis: Individual patient data meta-analysis」主題。共同形成了獨特的指紋。